Project Grant R01HL181107
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $721,977 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to uncover the molecular and functional organization of cardiovagal neurons that regulate heart rate through the vagus nerve. The project will map the synaptic inputs, outputs, and functional sufficiency of two distinct cardiovagal neuron subtypes—NPY2R-expressing neurons in the nucleus ambiguus and VIP-expressing neurons...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $802,973 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop rapid point-of-care molecular imaging of immune activation in acute coronary syndrome and acute myocarditis using targeted microbubble contrast agents. The project applies myocardial contrast echocardiography with phosphatidylserine-incorporating lipid microbubbles (MB-PS) to detect inflammatory activation from...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $248,999 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms regulating T-tubule structure in the mammalian heart during mechanical load conditions. The research will employ novel magnetorheological elastomer culture systems to subject isolated cardiomyocytes to pathological overload while comprehensively characterizing excitation-contraction...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $729,984 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 22, 2026. The award funds development of a three-dimensional real-time cardiovascular magnetic resonance imaging (3D RT CMR) reconstruction framework for imaging patients with cardiac arrhythmias. The proposed unsupervised reconstruction method, called Generative Prior with Multi-Dynamic Modeling (GEMM), enables highly accelerated 3D RT...
- The National Heart, Lung, and Blood Institute awarded $782,341 to the University of Pittsburgh on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate an adaptive, artificial intelligence-guided, closed-loop neuromodulation system for real-time prediction and prevention of ventricular arrhythmias in patients with prior myocardial infarction. The system will coordinate spinal cord stimulation and selective cardiac vagus nerve stimulation to...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $1,619,582 to the University of Virginia on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cardio-splenic axis in acute myocardial infarction and post-MI heart failure. The project examines the immunopathological mechanisms by which plasmacytoid dendritic cells orchestrate post-MI inflammation and cardiac dysfunction. The research team...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $133,221 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate precision electrophysiology imaging techniques for localizing cardiac arrhythmias. The recipient will use computed tomography and echocardiography imaging combined with electroanatomical mapping data to create three-dimensional visualization of arrhythmia...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $186,840 under CFDA 93.837 Cardiovascular Diseases Research on July 3, 2026, for advanced analysis of high-resolution cardiac diffusion tensor imaging (DTI). The funded work develops and applies DTI phenomapping, a voxel-level quantitative analysis approach for cardiac magnetic resonance imaging that resolves distinct microstructural patterns in...
The National Heart, Lung, and Blood Institute awarded the University of Virginia $760,465 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop deep learning methods that advance cardiac magnetic resonance strain imaging for personalized cardiac resynchronization therapy treatment planning. The award funds development of deep strain networks to rapidly and accurately predict myocardial displacements from cardiac magnetic resonance imaging, addressing the clinical challenge that 30–40 percent of heart failure patients receiving cardiac resynchronization therapy through traditional biventricular pacing are non-responders. Current strain imaging methods—feature tracking software accessible in commercial platforms but limited in segmental accuracy, or specialized techniques such as displacement encoding with stimulated echoes that produce highly accurate data but require extended scan times and are not widely available—create barriers to incorporating strain guidance into clinical practice. The project will leverage deep learning to overcome these limitations and establish strain-derived imaging features that can predict patient response and guide decisions between biventricular pacing and conduction system pacing approaches, particularly left bundle branch area pacing. Work is performed in Charlottesville, Virginia. The period of performance extends from August 1, 2026, through May 31, 2031. The award is classified as a Project Grant, an assistance type supporting discrete, circumscribed research projects under NIH peer-review competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $760.5k | 8/7/26 |